Drugs / Lartesertib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05396833 | Jun 2022 → Jan 2027 expected | cancer of unknown primary site | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04882917 | May 2021 → Mar 2023 | cancer | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06433219 | Oct 2024 → Jun 2026 overdue | ovarian carcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lartesertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05396833 ↗ |
| Known as | M4076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882917 ↗ |
| Action | Inhibit | “ATM Inhibitor M4076” NCT04882917 ↗ |
| Modality | Small molecule | — CHEMBL5314413 ↗ |
| Route | Oral | “M4076 was administered orally.” NCT04882917 ↗ |
| Target | ATM | “ATM Inhibitor M4076” NCT04882917 ↗ |